知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

786 条记录 (耗时 0.05 秒)

    Pharmaceutical antibody compositions with resistance to soluble CEA
    51.
    发明授权
    Pharmaceutical antibody compositions with resistance to soluble CEA 有权
    具有抗CEA抗性的药物抗体组合物

    公开(公告)号：US08901278B2

    公开(公告)日：2014-12-02

    申请号：US13324823

    申请日：2011-12-13

    申请人： Doris Rau ,  Susanne Mangold ,  Peter Kufer ,  Tobias Raum

    发明人： Doris Rau ,  Susanne Mangold ,  Peter Kufer ,  Tobias Raum

    IPC分类号： C07K16/30 ,  A61K39/00

    CPC分类号： C07K16/3007 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732

    摘要： The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” (SEQ ID NO: 29) and a CDR-H2 having the amino acid sequence “FIRNKANGGTTEYAASVKG” (SEQ ID NO: 28) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27) or (ii) a CDR-H1 having the amino acid sequence “TYAMH” (SEQ ID NO: 31) and a CDR-H2 having the amino acid sequence “LISNDGSNKYYADSVKG” (SEQ ID NO: 30) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27). Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed.

    摘要翻译： 本发明涉及用于治疗人类上皮肿瘤的药物组合物，所述药物组合物包含与人CEA特异性结合的IgG1抗体，其中所述IgG1抗体的可变区至少包含（i）具有 氨基酸序列“SYWMH”（SEQ ID NO：29）和具有氨基酸序列“FIRNKANGGTTEYAASVKG”（SEQ ID NO：28）的CDR-H2和具有氨基酸序列“DRGLRFYFDY”（SEQ ID NO： （SEQ ID NO：31）的CDR-H1和具有氨基酸序列“LISNDGSNKYYADSVKG”（SEQ ID NO：30）的CDR-H2和CDR -H3，具有氨基酸序列“DRGLRFYFDY”（SEQ ID NO：27）。 此外，公开了用于生产所述药物组合物的方法以及具有人CEA抗原特异性的IgG1抗体分子的医疗/药物用途。

    Mammalian cell lines for increasing longevity and protein yield from a cell culture
    53.
    发明授权
    Mammalian cell lines for increasing longevity and protein yield from a cell culture 有权
    用于从细胞培养物增加寿命和蛋白质产量的哺乳动物细胞系

    公开(公告)号：US08889410B2

    公开(公告)日：2014-11-18

    申请号：US14290099

    申请日：2014-05-29

    申请人： Immunomedics, Inc.

    发明人： David M. Goldenberg ,  Zhengxing Qu ,  Chien-Hsing Chang ,  Edmund A. Rossi ,  Jeng-Dar Yang ,  Diane Rossi

    IPC分类号： C12N5/00 ,  C12N15/00 ,  C12P21/00 ,  C07K16/28

    CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K14/005 ,  C07K14/4747 ,  C07K16/00 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/3007 ,  C07K2317/24 ,  C07K2317/31 ,  C12N5/0694 ,  C12N15/85 ,  C12N15/86 ,  C12N2500/90 ,  C12N2501/48 ,  C12N2510/02 ,  C12N2710/20022 ,  C12N2740/10043 ,  C12P21/02

    摘要： Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.

    摘要翻译： 公开了用于增加细胞培养物的寿命并允许增加蛋白质生产的组合物和方法，优选重组蛋白，例如抗体，肽，酶，生长因子，白细胞介素，干扰素，激素和疫苗。 用凋亡抑制基因或载体如三重突变体Bcl-2基因转染的细胞可以在培养物中更长时间地存活，导致蛋白质生物合成的状态和产量的延长。 这样的转染细胞表现出最大的细胞密度，其等于或超过由亲本细胞系实现的最大密度。 转染的细胞也可以预先适应于无血清培养基中生长，大大减少了在无血清培养基中获得蛋白质产生所需的时间。 在某些方法中，预先调节的细胞可以在无血清条件下转化后用于蛋白质生产。 该方法优选涉及真核细胞，更优选哺乳动物细胞。

    COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE
    60.
    发明申请
    COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE 有权
    用于诱发免疫应答疾病的组合治疗

    公开(公告)号：US20140099254A1

    公开(公告)日：2014-04-10

    申请号：US14106737

    申请日：2013-12-14

    申请人： IBC Pharmaceuticals, Inc.

    发明人： Chien-Hsing Chang ,  David M. Goldenberg ,  Edmund A. Rossi ,  Diane Rossi

    IPC分类号： A61K38/21 ,  A61K47/48 ,  A61K45/06 ,  A61K39/395

    CPC分类号： A61K39/3955 ,  A61K9/0019 ,  A61K38/21 ,  A61K38/212 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6851 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/44 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  A61K2300/00

    摘要： The present invention concerns combinations of two or more agents for inducing an immune response to cancer or infectious disease. Agents may include leukocyte redirecting complexes, antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The leukocyte redirecting complexes have at least one binding site for a leukocyte antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3×anti-CD19 bispecific antibody, although antibodies against other leukocyte antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of cells associated with cancer or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.

    摘要翻译： 本发明涉及用于诱导对癌症或感染性疾病的免疫应答的两种或更多种试剂的组合。 试剂可以包括白细胞重定向复合物，抗体 - 药物偶联物，干扰素（优选干扰素-α）和/或检查点抑制剂抗体。 白细胞重定向复合物具有白细胞抗原的至少一个结合位点和患病细胞或病原体上的抗原的至少一个结合位点。 优选地，复合物是DNL TM复合物。 更优选地，复合物包含双特异性抗体（bsAb）。 最优选地，bsAb是抗CD3×抗CD19双特异性抗体，尽管可以使用针对其它白细胞抗原和/或疾病相关抗原的抗体。 该复合物能够靶向效应T细胞，NK细胞，单核细胞或嗜中性粒细胞，以诱导与癌症或感染性疾病相关的细胞的白细胞介导的细胞毒性。 通过共同给予干扰素，检查点抑制剂抗体和/或ADC来增强细胞毒性免疫应答。